Abstract:ABSTRAKT Einführung Periodisches Fieber, aphthöse Stomatitis, Pharyngitis und zervikales Adenitis-Syndrom (PFAPA) ist die häufigste periodische Fiebererkrankung bei Kindern. Es besteht kein Konsens über die Behandlung, um Anfällen vorzubeugen und ihre Häufigkeit zu verringern. In dieser Studie wollten wir die Wirksamkeit der Colchicin-Behandlung beim PFAPA-Syndrom bewerten. Darüber hinaus haben wir die demografischen und klinischen Merkmale von PFAPA-Patienten beschrieben. Materialen und Methoden Wir haben retrospektiv 58 PFAPA-Patienten analysiert, die zwischen Januar 2017 und Januar 2022 mit einer Colchicin-Behandlung begonnen hatten. Dabei wurden demografische Daten, klinische Merkmale, Labortests, genetische Analysen von Mutationen des Mittelmeerfiebers (MEFV) und Werte des Autoinflammatorischen Krankheitsaktivitätsindex (AIDAI) ausgewertet alle Patienten Darüber hinaus wurden die Patienten nach MEFV-Varianten in zwei Gruppen eingeteilt und verglichen. Ergebnisse Anfallshäufigkeit, -dauer und AIDAI-Scores sanken bei allen Patienten nach der Colchicin-Behandlung. Die Nachbeobachtungszeit betrug 13,53 ± 6,65 Monate. Das mittlere ± IQR-Alter bei der Diagnose betrug 3,2 (2–5) Jahre. Dreiunddreißig (56,9 %) Patienten hatten heterozygote MEFV-Mutationen. Die häufigsten MEFV-Varianten waren M694V (63,6 %). Es gab keinen signifikanten Unterschied zwischen den beiden Gruppen hinsichtlich der Colchicin-Reaktionen. Abschluss Die Behandlung mit Colchicin ist wirksam und sicher bei Patienten mit PFAPA, die häufig an Anfällen leiden. Es wurde kein Zusammenhang zwischen dem Vorhandensein heterozygoter MEFV-Mutationen und der Colchicin-Reaktion festgestellt. ABSTRACT Introduction Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome (PFAPA) is the most common periodic fever condition in children. There is no consensus on treatment to prevent attacks and reduce their frequency. In this study, we aimed to evaluate the effectiveness of colchicine treatment in PFAPA syndrome. In addition, we described the demographic and clinical features of PFAPA patients. Materials and Methods We retrospectively analyzed 58 PFAPA patients who were started on colchicine treatment between January 2017 and January 2022. Demographic data, clinical features, laboratory tests, genetic analysis of MEditerranean FeVer (MEFV) mutations, and autoinflammatory disease activity index (AIDAI) scores of all patients were evaluated. In addition, patients were divided into two groups according to MEFV variants and compared. Results Attack frequency, duration, and AIDAI scores decreased in all patients after colchicine treatment. Duration of follow-up was 13.53±6.65 months. The median±IQR age at diagnosis was 3.2 (2-5) years. Thirty three (56.9 %) patients had heterozygous mutations of MEFV. The most common MEFV variants were M694V (63.6 %). There was no significant difference between the two groups in terms of colchicine responses. Conclusion Colchicine treatment is effective and safe in patients with PFAPA who have frequent attacks. No association was established between the presence of heterozygous mutations of MEFV and colchicine response.

The journey of MEFV heterozygous children: with or without colchicine

Gray zone in the spectrum of autoinflammatory diseases: familial Mediterranean fever accompanying periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome: single-center experience

Factors Associated With Successful Withdrawal of Biologic Agents in Children With Colchicine-Resistant Familial Mediterranean Fever

Mutations in the MEFV Gene in a Large Series of Patients with a Clinical Diagnosis of Familial Mediterranean Fever.

Colchicine-intolerant familial mediterranean fever patients: A comparative study between different colchicine doses and IL-1 inhibitor monotherapy

Molecular investigation of MEFV gene polymorphisms among patients with familial mediterranean fever-like symptoms

MEFV-Gene Analysis in Armenian Patients with Familial Mediterranean Fever: Diagnostic Value and Unfavorable Renal Prognosis of the M694V Homozygous Genotype—Genetic and Therapeutic Implications

Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever – a randomized controlled noninferiority trial

Einfluss der Colchicin-Behandlung auf den klinischen Verlauf bei Kindern mit PFAPA-Syndrom

The significance of carrying MEFV variants in symptomatic and asymptomatic individuals

Genotypic Diagnosis of Familial Mediterranean Fever (FMF) Using New Microsatellite Markers: Example of Two Extensive Non-Ashkenazi Jewish Pedigrees.

Colchicine Modulates Oxidative Stress in Serum and Leucocytes from Remission Patients with Family Mediterranean Fever Through Regulation of Ca2+ Release and the Antioxidant System

Inflammatory biomarker analysis confirms reduced disease severity in heterozygous patients with familial Mediterranean fever

Effect of interleukin-1 antagonist on growth of children with colchicine resistant or intolerant FMF

Colchicine – an effective treatment for children with a clinical diagnosis of autoinflammatory diseases without pathogenic gene variants

Treatment Indications and Clinical Features in a Large Real-World Cohort

Canakinumab treatment in children with familial Mediterranean fever: report from a single center

Methylenetetrahydrofolate reductase polymorphism in childhood primary focal segmental glomerulosclerosis.

Clinical Versus Genetic Diagnosis of Familial Mediterranean Fever.

The grandfather’s fever

Familial Mediterranean fever in Armenian children with inflammatory bowel disease